-
Pluri (PLUR) files $200M mixed shelf
-
Plurilock and ADGA partner to support Canadian defence supplier certification
-
Plurilock Signs Collaboration Agreement with ADGA to Support Defence Suppliers Pursuing CPCSC Certification
-
Pluri's Cellav unit completes UK regulatory registration for aesthetics product
-
Pluri in talks with EIB over €20M loan resolution
-
Pluri receives $1.25M advance from chairman-owned entity
-
Pluri regains Nasdaq compliance after appointing audit committee chair
-
Brainstorm Cell Therapeutics (BCLI) Secures Manufacturing Partnership with Minaris
-
Pluri (PLUR) Announces Two New Patents for 3D Expansion of Immune Cells in the United States and Israel
-
Pluri (PLUR) Announces Exclusive Collaboration Agreement with Hemafund
-
Pluri (PLUR) Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness
-
Pluri (PLUR) Secures Additional $3.5M Investment from Major Shareholder
-
Pluri (PLUR) Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition
-
Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event
-
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
-
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
-
Pluri's (PLUR) CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
-
Pluri (PLUR) Announces EUR 1M Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
-
Pluri (PLUR) Announces CFO Resignation
-
Pluri's (PLUR) Ever After Foods Secured $10M Strategic Investment


